Reimagining Drug Discovery with Frontier AI: From Molecules to Medicine | AI House Davos 2026

How is AI compressing the path from target hypothesis to designed molecules? What diseases become solvable when we redesign discovery itself? AI is learning the rules of biology and rewriting the pace of drug discovery. This session explores how generative and predictive models are compressing the path from target hypothesis to designed molecules and proteins. We'll unpack what it takes to move from promising outputs to trustworthy decisions, through rigorous validation, reproducible workflows, and governance that builds trust with scientific and regulatory stakeholders. Beyond productivity, the session asks a deeper question: what diseases become solvable when we redesign discovery itself? Speakers Aldo Faisal (Imperial College London, Professor in AI & Neuroscience) Colin Hill (Aitia, Co-Founder and CEO) Noubar Afeyan (Flagship Pioneering, CEO) Fiona Marshall (Novartis, President Biomedical Research) Moderator Nikita Popov (Novartis, Head of AI Strategy Office) (c) AI House Davos 2026 Founders & Strategic Partners: ETH AI Center, Merantix, G42, Hewlett Packard Enterprise, EPFL AI Center, The University of Tokyo Presenting Partners: KPMG